The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts have set 12-month price targets for DexCom, revealing an average target of $97.15, a high estimate of $106.00, and a ...

Fintel reports that on October 21, 2025, Stifel reiterated coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation.

We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ ...

Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. This analytical report serves as a pivotal resource for detailed insights into Dexcom's expansive pipeline, ...

San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A ...

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. DexCom’s ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...

DexCom (DXCM) shares are in the spotlight after the company delivered better-than-expected second quarter revenues. However, a softer full-year outlook has drawn investor caution. Sector-wide trade ...